Cargando…
Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures
INTRODUCTION: Severe hypersensitivity reactions (HSRs) such as anaphylaxis are of great clinical concern because of their life-threatening potential. The adverse events attributable to intravenous iron products include HSRs. An investigation by the European Medicines Agency presented in late 2013 re...
Autores principales: | Nathell, Lennart, Gohlke, Annegret, Wohlfeil, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965341/ https://www.ncbi.nlm.nih.gov/pubmed/31583644 http://dx.doi.org/10.1007/s40264-019-00868-5 |
Ejemplares similares
-
Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2020) -
Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018) -
Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
por: Ehlken, Birgit, et al.
Publicado: (2019) -
Hypersensitivity to Intravenous Iron Preparations
por: Caimmi, Silvia, et al.
Publicado: (2022) -
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)